keyword
MENU ▼
Read by QxMD icon Read
search

Trial,esrd and renoprotective

keyword
https://www.readbyqxmd.com/read/27829948/increased-hematocrit-during-sodium-glucose-cotransporter-2-inhibitor-therapy-indicates-recovery-of-tubulointerstitial-function-in-diabetic-kidneys
#1
REVIEW
Motoaki Sano, Makoto Takei, Yasuyuki Shiraishi, Yoshihiko Suzuki
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been attracting attention for cardiovascular as well as antidiabetic effects since the results of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME Trial) were reported. The hematocrit increases during treatment with SGLT2 inhibitors, which have a diuretic effect but do not cause sufficient hemoconcentration to increase the risk of cerebral infarction. Elevation of the hematocrit during SGLT2 inhibitor therapy is presumed to involve enhancement of erythropoiesis in addition to hemoconcentration...
December 2016: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/27583237/the-effect-of-renin-angiotensin-system-inhibitors-on-kidney-allograft-survival-a-systematic-review-and-meta-analysis
#2
Wisit Cheungpasitporn, Charat Thongprayoon, Michael A Mao, Wonngarm Kittanamongkolchai, Insara J J Sathick, Stephen B Erickson
BACKGROUND: The use of renin-angiotensin system (RAS) inhibitors in patients with chronic kidney disease, and especially in diabetic kidney disease, has been shown to provide renoprotective effects and slow progression to end-stage renal disease. However, this protective effect in kidney transplant patient populations is unclear. AIM: The objective of this systematic review and meta-analysis was to evaluate the effect of RAS inhibitors on kidney allograft survival...
July 2016: North American Journal of Medical Sciences
https://www.readbyqxmd.com/read/27144163/fsgs-recurrence-in-adults-after-renal-transplantation
#3
REVIEW
Michael Rudnicki
Recurrence of focal segmental glomerulosclerosis (FSGS) in the allograft occurs in 30-50% of patients, and it is associated with poor renal allograft survival. Major risk factors for recurrence are younger age at diagnosis, rapid progression to end-stage renal disease, white race, and the loss of previous allografts due to recurrence. Recent data support the hypothesis that circulating permeability factors play a crucial role in podocyte injury and progression of FSGS. Due to lack of controlled trials, the management of recurrent FSGS is inconsistent and highly empirical...
2016: BioMed Research International
https://www.readbyqxmd.com/read/27113485/phosphodiesterase-type-5-inhibition-reduces-albuminuria-in-subjects-with-overt-diabetic-nephropathy
#4
Wim Scheele, Susan Diamond, Jeremy Gale, Valerie Clerin, Nihad Tamimi, Vu Le, Rosalind Walley, Fernando Grover-Páez, Christelle Perros-Huguet, Timothy Rolph, Meguid El Nahas
Diabetic nephropathy (DN) is the leading cause of ESRD worldwide. Reduced bioavailability or uncoupling of nitric oxide in the kidney, leading to decreased intracellular levels of the nitric oxide pathway effector molecule cyclic guanosine monophosphate (cGMP), has been implicated in the progression of DN. Preclinical studies suggest that elevating the cGMP intracellular pool through inhibition of the cGMP-hydrolyzing enzyme phosphodiesterase type 5 (PDE5) might exert renoprotective effects in DN. To test this hypothesis, the novel, highly specific, and long-acting PDE5 inhibitor, PF-00489791, was assessed in a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group trial of subjects with type 2 diabetes mellitus and overt nephropathy receiving angiotensin converting enzyme inhibitor or angiotensin receptor blocker background therapy...
November 2016: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/27055479/effect-of-calcium-channels-blockers-and-inhibitors-of-the-renin-angiotensin-system-on-renal-outcomes-and-mortality-in-patients-suffering-from-chronic-kidney-disease-systematic-review-and-meta-analysis
#5
Hong-Jin Zhao, Yan Li, Shan-Mei Liu, Xiang-Guo Sun, Min Li, Yan Hao, Lian-Qun Cui, Ai-Hong Wang
BACKGROUND: The renoprotective effect of inhibitors of renin-angiotensin system (RAS) has been identified through placebo-controlled trials. However, the effect of calcium-channel blockers (CCBs) on renal system is still controversial. Our current meta-analysis includes available evidences to compare the effect of dihydropyridine CCBs and ACEIs or ARBs on renal outcomes and mortality. We also further investigate whether CCBs can be used in combination with inhibitors of RAS to improve the prognosis of patients with chronic kidney disease (CKD)...
July 2016: Renal Failure
https://www.readbyqxmd.com/read/26992264/effects-of-renin-angiotensin-aldosterone-system-blockade-in-patients-with-end-stage-renal-disease
#6
REVIEW
Teresa Slomka, Emily S Lennon, Hina Akbar, Elvira O Gosmanova, Syamal K Bhattacharya, Carrie S Oliphant, Rami N Khouzam
Blockers of the renin-angiotensin-aldosterone system (RAAS), such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are routinely used in patients with chronic kidney disease because of their cardiovascular (CV) and renoprotective effects. However, there are no uniform recommendations about RAAS blockers for CV protection in the end-stage renal disease (ESRD) population other than the preferred drug class for blood pressure control. This uncertainty stems from the fact that patients with ESRD were generally excluded from randomized controlled trials evaluating the cardioprotective benefits of RAAS blockers...
March 2016: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/26904991/renoprotective-effect-of-the-combination-of-renin-angiotensin-system-inhibitor-and-calcium-channel-blocker-in-patients-with-hypertension-and-chronic-kidney-disease
#7
Rong-Shuang Huang, Yi-Ming Cheng, Xiao-Xi Zeng, Sehee Kim, Ping Fu
BACKGROUND: Renin-angiotensin system inhibitor and calcium channel blocker (CCB) are widely used in controlling blood pressure (BP) in patients with chronic kidney disease (CKD). We carried out a meta-analysis to compare the renoprotective effect of the combination of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and CCB (i.e., ACEI/ARB + CCB) with ACEI/ARB monotherapy in patients with hypertension and CKD. METHODS: Publications were identified from PubMed, Embase, Medline, and Cochrane databases...
March 5, 2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/26239552/endothelin-blockade-in-diabetic-kidney-disease
#8
REVIEW
Lidia Anguiano, Marta Riera, Julio Pascual, María José Soler
Diabetic kidney disease (DKD) remains the most common cause of chronic kidney disease and multiple therapeutic agents, primarily targeted at the renin-angiotensin system, have been assessed. Their only partial effectiveness in slowing down progression to end-stage renal disease, points out an evident need for additional effective therapies. In the context of diabetes, endothelin-1 (ET-1) has been implicated in vasoconstriction, renal injury, mesangial proliferation, glomerulosclerosis, fibrosis and inflammation, largely through activation of its endothelin A (ETA) receptor...
May 25, 2015: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/26152402/effects-of-blood-pressure-on-renal-and-cardiovascular-outcomes-in-asian-patients-with-type-2-diabetes-and-overt-nephropathy-a-post-hoc-analysis-orient-blood-pressure
#9
MULTICENTER STUDY
Enyu Imai, Sadayoshi Ito, Masakazu Haneda, Atsushi Harada, Fumiaki Kobayashi, Tetsu Yamasaki, Hirofumi Makino, Juliana C N Chan
BACKGROUND: Blood pressure (BP) control may have different effects on cardiovascular (CV) and renal outcomes in diabetes. We examined the impact of systolic BP (SBP) on renal and CV outcomes in a post hoc analysis in the Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial. METHODS: We stratified mean follow-up SBP into three categories (≤130, 131-140 and >140 mmHg) and used a Cox regression model to estimate the hazard ratio (HR, 95% confidence interval) for the outcomes...
March 2016: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/25943756/pleiotropic-effects-of-type-2-diabetes-management-strategies-on-renal-risk-factors
#10
REVIEW
Marcel H A Muskiet, Lennart Tonneijck, Mark M Smits, Mark H H Kramer, Hiddo J Lambers Heerspink, Daniël H van Raalte
In parallel with the type 2 diabetes pandemic, diabetic kidney disease has become the leading cause of end-stage renal disease worldwide, and is associated with high cardiovascular morbidity and mortality. As established in landmark randomised trials and recommended in clinical guidelines, prevention and treatment of diabetic kidney disease focuses on control of the two main renal risk factors, hyperglycaemia and systemic hypertension. Treatment of systemic hypertension with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers is advocated because these drugs seem to exert specific renoprotective effects beyond blood pressure lowering...
May 2015: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/25872610/the-renal-protective-effect-of-angiotensin-receptor-blockers-depends-on-intra-individual-response-variation-in-multiple-risk-markers
#11
RANDOMIZED CONTROLLED TRIAL
Bauke Schievink, Dick de Zeeuw, Hans-Henrik Parving, Peter Rossing, Hiddo Jan Lambers Heerspink
AIMS: Angiotensin receptor blockers (ARBs) are renoprotective and targeted to blood pressure. However, ARBs have multiple other (off-target) effects which may affect renal outcome. It is unknown whether on-target and off-target effects are congruent within individuals. If not, this variation in short term effects may have important implications for the prediction of individual long term renal outcomes. Our aim was to assess intra-individual variability in multiple parameters in response to ARBs in type 2 diabetes...
October 2015: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/25531311/dual-renin-angiotensin-system-blockade-for-nephroprotection-still-under-scrutiny
#12
REVIEW
Giorgio Gentile, Giuseppe Remuzzi, Piero Ruggenenti
In experimental diabetic and non-diabetic chronic kidney disease (CKD), angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) combination therapy reduces proteinuria and prevents structural lesions more effectively than either drug alone. Consistently, in humans, a multidrug individually tailored antiproteinuric treatment based on combination therapy with maximum tolerated doses of ACEi and ARB (Remission Clinic protocol) reduced proteinuria and prevented end-stage renal disease (ESRD) more effectively than ACEi/ARB monotherapy, in particular in subjects with non-diabetic CKD...
2015: Nephron
https://www.readbyqxmd.com/read/25421558/drug-induced-reduction-in-albuminuria-is-associated-with-subsequent-renoprotection-a-meta-analysis
#13
REVIEW
Hiddo J Lambers Heerspink, Tobias F Kröpelin, Jarno Hoekman, Dick de Zeeuw
Albuminuria has been proposed as a surrogate end point in randomized clinical trials of renal disease progression. Most evidence comes from observational analyses showing that treatment-induced short-term changes in albuminuria correlate with risk change for ESRD. However, such studies are prone to selection bias and residual confounding. To minimize this bias, we performed a meta-analysis of clinical trials to correlate the placebo-corrected drug effect on albuminuria and ESRD to more reliably delineate the association between changes in albuminuria and ESRD...
August 2015: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/24986448/low-protein-diet-for-diabetic-nephropathy
#14
REVIEW
Toshiki Otoda, Keizo Kanasaki, Daisuke Koya
Diabetic nephropathy is the leading cause of progressive kidney disease, leading to end-stage renal disease and renal replacement therapy. Angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers have been considered effective at slowing the progression of kidney function deterioration. However, these drugs cannot sufficiently halt the progression of nephropathy to the extent that is required. A low-protein diet (LPD) is believed to be a nutritional intervention that may slow kidney disease progression...
2014: Current Diabetes Reports
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"